C039P: Abciximab Biosimilar (Research Grade), Anti-human Glycoprotein IIb/IIIa Receptor Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody abciximab biosimilar specifically binds to the human Glycoprotein IIb/IIIa Receptor protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by abciximab.C003P: Adalimumab Biosimilar, TNF alpha Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.C040P: Alemtuzumab Biosimilar, CD52 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody alemtuzumab biosimilar specifically binds to the human CD52, a protein present on the surface of mature lymphocytes.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by alemtuzumab.PA007618.m1:In Vivo Grade Recombinant Anti-human MHC Class II HLA-DP/DQ/DR Monoclonal Antibody (Clone: IVA12), Mouse IgG1 Kappa
Recombinant Mouse IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: IVA12) specifically binds to human MHC Class II HLA-DP/DQ/DR.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human MHC Class II HLA-DP/DQ/DR protein.C001P: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Specificity/Sensitivity: The monoclonal antibody bevacizumab biosimilar specifically binds to the human VEGF-A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.C002P: Cetuximab Biosimilar, Human EGFR Monoclonal Antibody
Recombinant Chimeric IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody cetuximab biosimilar specifically binds to the human EGFR.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cetuximab.C004P: Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Recombinant Humanized IgG2 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.C022P: Eculizumab Biosimilar, Human C5 Monoclonal Antibody
Recombinant Humanized IgG2/4 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays.C075P: Etanercept Biosimilar
Recombinant protein composed of the soluble TNF receptor 2 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Specificity/Sensitivity: The etanercept biosimilar protein specifically binds to the human TNF alpha.
Applications: Functional assays, and those assays for studying biological pathways affected by etanercept.C011P: Infliximab Biosimilar, TNF alpha Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.